StockData
Phibro Animal Health Corp logo

Phibro Animal Health Corp (PAHC) company profile

PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 22/3046% below fair value
$34.92−0.10 (-0.29%)

Close on Nov 17, 2026Market cap $1.42BP/E 14.4Yield 1.37%

About Phibro Animal Health

Pharmaceutical Preparations, SIC 2834

Phibro Animal Health Corporation develops, manufactures, and sells animal health and mineral nutrition products, alongside specialty industrial chemicals. The business operates across three segments: Animal Health, Mineral Nutrition, and Performance Products. Offerings include antibacterials, anticoccidials, nutritional specialty products, vaccines, vaccine adjuvants, ethanol fermentation aids, fortifying mineral diets, and chemical catalyst ingredients. The company serves livestock producers, animal feed manufacturers, wholesalers, distributors, veterinarians, and industrial clients, targeting food animals such as poultry, cattle, and swine, as well as companion animals.

The company markets approximately 790 product lines to around 4,800 customers in about 90 countries. Its operations extend across North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East, with manufacturing facilities in the United States, Italy, and China. Phibro is incorporated in Delaware, though the provided text does not state a headquarters location.

Summary of the business section of Phibro Animal Health's latest annual report, written by StockData.

Company profile

Company

Legal name
Phibro Animal Health Corp
Headquarters
Teaneck, NJ
Address
Glenpointe Centre East, 3rd Floor, 300 Frank W. Burr Blvd., Suite 21 07666
Phone
(201) 329-7300
Employees
2,605, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
June 30
Auditor
PricewaterhouseCoopers LLP, Florham Park, New Jersey

Stock & identifiers

Ticker
PAHC
Exchange
Nasdaq
IPO date
Apr 11, 2014
Shares outstanding
41M, Aug 21, 2026
Public float
$763.70M, Dec 31, 2025
Filer category
Large accelerated filer
SEC CIK
1069899
CUSIP
71742Q106
ISIN
US71742Q1067
FIGI
BBG000C31ZH2
Share class FIGI
BBG0069NW5X3
LEI
549300U24SP4AF2JUX52
EIN
13-1840497

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Daniel M. BendheimPresident and CEO, Director15,177
Jack BendheimExecutive Chairman, Director39,996,860
Larry Lee MillerChief Operating Officer38,275
Glenn DavidChief Financial Officer54,959
Patrick RodriguezVP Finance and Treasurer1,503
Judith WeinsteinSee Remarks5,453
Lisa Ann EscuderoSee Remarks3,434
Anthony AndolinoSee Remarks1,793
Jonathan BENDHEIMDirector5,984
E. Thomas CorcoranDirector41,459
Joyce J. LeeDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$5.23M$5.20M$1.48M$123$136
FY2025$5.28M$5.12M$1.47M$111$99
FY2024$4.75M$3.96M$1.32M$72$97
FY2023$2.94M$2.90M$630.06K$56$98
FY2022$3.61M$3.56M$803.85K$76$100
FY2021$4.00M$3.69M$943.33K$112$121

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsIncentive payOtherTotalvs. prior year
Jack C. Bendheim
Chairman of the Board and Executive Chairman
$2.44M–$424.26K$1.59M$775.35K$5.23M-1%
Daniel M. Bendheim
President and Chief Executive Officer
$575.00K–$99.87K$373.75K$71.48K$1.12M+0%
Glenn David
Chief Financial Officer
$702.77K–$122.06K$456.80K$52.09K$1.33M+5%
Larry L. Miller
Chief Operating Officer
$751.85K$1.06M$130.60K$488.70K$66.97K$2.50M+3%
Judith Weinstein
Senior Vice President, General Counsel and Corporate Secretary
$500.00K–$86.84K$325.00K$63.35K$975.19K-7%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of June 30, 2026, we had approximately 2,605 employees in 75 locations spanning 37 countries.”

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 31, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 25, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 8, 2014ListingRegistration of securities on an exchange (Form 8-A)
Jul 26, 2006DeregistrationTermination of SEC registration (Form 15)
Feb 15, 2005Late filingNotification of late filing
Jan 14, 2005MergerRegistration of securities for a merger or exchange offer (S-4)
Feb 18, 2004MergerRegistration of securities for a merger or exchange offer (S-4)
May 14, 2003Name changeName changed from PHILIPP BROTHERS CHEMICALS INC to Phibro Animal Health Corp
Sep 30, 2002Late filingNotification of late filing
Sep 28, 2001Late filingNotification of late filing
Sep 29, 1998MergerRegistration of securities for a merger or exchange offer (S-4)

See a number that looks wrong?